Valley Brook Capital Group Inc. Purchases 100 Shares of Zoetis Inc. (NYSE:ZTS)

Valley Brook Capital Group Inc. increased its position in Zoetis Inc. (NYSE:ZTS) by 4.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,168 shares of the company’s stock after purchasing an additional 100 shares during the quarter. Valley Brook Capital Group Inc.’s holdings in Zoetis were worth $428,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Cary Street Partners Investment Advisory LLC lifted its position in Zoetis by 7.4% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 93,735 shares of the company’s stock worth $16,308,000 after purchasing an additional 6,457 shares during the period. Peak Financial Advisors LLC acquired a new position in Zoetis during the fourth quarter worth $2,776,000. Ninety One UK Ltd raised its stake in Zoetis by 13.1% during the fourth quarter. Ninety One UK Ltd now owns 108,293 shares of the company’s stock worth $21,374,000 after acquiring an additional 12,537 shares in the last quarter. Raymond James Financial Services Advisors Inc. raised its stake in Zoetis by 10.9% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 183,564 shares of the company’s stock worth $36,230,000 after acquiring an additional 17,976 shares in the last quarter. Finally, Advisor Partners II LLC raised its stake in Zoetis by 4.0% during the third quarter. Advisor Partners II LLC now owns 24,068 shares of the company’s stock worth $4,187,000 after acquiring an additional 922 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of the firm’s stock in a transaction dated Thursday, April 18th. The stock was sold at an average price of $151.17, for a total transaction of $139,529.91. Following the transaction, the executive vice president now owns 14,800 shares in the company, valued at $2,237,316. The sale was disclosed in a document filed with the SEC, which is available through this link. Over the last quarter, insiders have sold 2,209 shares of company stock worth $371,293. Insiders own 0.16% of the company’s stock.

Zoetis Trading Down 0.1 %

Zoetis stock traded down $0.16 during mid-day trading on Friday, hitting $167.07. The stock had a trading volume of 3,007,125 shares, compared to its average volume of 4,607,073. The stock has a 50-day simple moving average of $168.88 and a two-hundred day simple moving average of $178.93. The stock has a market capitalization of $76.41 billion, a PE ratio of 32.19, a P/E/G ratio of 2.61 and a beta of 0.86. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92. The company has a current ratio of 3.36, a quick ratio of 2.00 and a debt-to-equity ratio of 1.32.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.04. The business had revenue of $2.19 billion for the quarter, compared to analysts’ expectations of $2.14 billion. Zoetis had a return on equity of 50.74% and a net margin of 27.38%. The firm’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same quarter last year, the business earned $1.31 earnings per share. As a group, sell-side analysts forecast that Zoetis Inc. will post 5.77 EPS for the current year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be issued a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a yield of 1.03%. The ex-dividend date of this dividend is Thursday, April 18th. Zoetis’s dividend payout ratio (DPR) is currently 33.33%.

Wall Street Analyst Weigh In

Several research analysts have issued reports on ZTS shares. Stifel Nicolaus dropped their price objective on Zoetis from $195.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, April 30th. Barclays lowered their target price on Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a research note on Tuesday, April 23rd. StockNews.com lowered Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. The Goldman Sachs Group raised their target price on Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a research note on Wednesday, January 17th. Finally, Piper Sandler restated an “overweight” rating and issued a $195.00 target price (down from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $216.13.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.